Literature DB >> 19350612

A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.

Wolfgang Reindl1, Juping Yuan, Andrea Krämer, Klaus Strebhardt, Thorsten Berg.   

Abstract

Playing polo: Small-molecule inhibitors of polo-like kinase 1 are mostly ATP-competitive, and thus face enormous specificity hurdles. This communication explores the concept of inhibiting Plk1 with a small-molecule inhibitor of the protein-protein interactions required for Plk1 function.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19350612     DOI： 10.1002/cbic.200900059

Source DB:  PubMed          Journal:  Chembiochem        ISSN： 1439-4227            Impact factor:   3.164


  25 in total

1.  Investigation of unanticipated alkylation at the N(π) position of a histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues.

Authors:  Wenjian Qian; Fa Liu; Terrence R Burke
Journal:  J Org Chem       Date:  2011-10-03       Impact factor: 4.354

2.  Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Authors:  Juping Yuan; Mourad Sanhaji; Andrea Krämer; Wolfgang Reindl; Matthias Hofmann; Nina-Naomi Kreis; Brigitte Zimmer; Thorsten Berg; Klaus Strebhardt
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

Review 3.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

4.  Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.

Authors:  Wen-Jian Qian; Jung-Eun Park; Dan Lim; Suk-Youl Park; Ki-Won Lee; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Chem Biol       Date:  2013-10-10

Review 5.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 6.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

Review 7.  Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.

Authors:  Ravichandran N Murugan; Jung-Eun Park; Eun-Hee Kim; Song Yub Shin; Chaejoon Cheong; Kyung S Lee; Jeong Kyu Bang
Journal:  Mol Cells       Date:  2011-07-29       Impact factor: 5.034

Review 8.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.

Authors:  Wenjian Qian; Jung-Eun Park; Fa Liu; Kyung S Lee; Terrence R Burke
Journal:  Bioorg Med Chem       Date:  2012-05-26       Impact factor: 3.641

10.  Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.

Authors:  Wen-Jian Qian; Jung-Eun Park; Dan Lim; Christopher C Lai; James A Kelley; Suk-Youl Park; Ki Won Lee; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Biopolymers       Date:  2014-11       Impact factor: 2.505
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.